Abstract
Systemic autoinflammatory diseases (SAIDs) are a heterogeneous group of chronic disorders driven by dysregulated innate immune responses, with monogenic or polygenic/multifactorial etiology. While some monogenic SAIDs benefit from targeted therapies, many “undefined” SAIDs (uSAIDs) lack molecular diagnostics and specific treatments. Understanding autoantibody profiles and immune response heterogeneity is critical for improving classification, diagnostics, and personalized therapy development. Our study aimed to define distinct autoantibody profiles, evaluate immune response heterogeneity, and analyze correlations between autoantibody reactivity and clinical parameters. We hypothesized that specific autoantibody signatures correlate with SAID phenotypes and disease progression, providing insights into pathogenesis to enhance SAID diagnosis, prognosis, and management in clinical practice.
This is part of a large multi-omics approach in categorizing uSAIDs.
This is part of a large multi-omics approach in categorizing uSAIDs.
Originalsprache | Englisch |
---|---|
Publikationsstatus | Veröffentlicht - 12 Feb. 2025 |
Veranstaltung | EP Permed - midterm seminar and Conference on Personalised Medicine Research: European Partnership for personalized Medicine - Berlin, Deutschland Dauer: 12 Feb. 2025 → 13 Feb. 2025 https://www.eppermed.eu/news-events/events/ep-permed-conference-on-personalised-medicine-research/ |
Konferenz
Konferenz | EP Permed - midterm seminar and Conference on Personalised Medicine Research |
---|---|
Land/Gebiet | Deutschland |
Stadt | Berlin |
Zeitraum | 12/02/25 → 13/02/25 |
Internetadresse |
Research Field
- Molecular Diagnostics
Schlagwörter
- immunoassay
- Immunoglobulin G
- bioinformatics
- Bioinformatics
- precision medicine